SYN-002 (Synactix)

N/A

Report date: 2025/01/26 15:50:52
NME

Base Information

Drug NameSYN-002 (Synactix)
Drug Alias Nameaurora B kinase inhibitor (Synactix)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-B inhibitors
TargetsSerine/threonine-protein kinase Aurora-B
Therapy Area/IndicationsLeukemia, Myeloid, AcuteNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSynactix Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSynactix Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A